会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Farnesyl transferase inhibitors, preparation thereof and pharmaceutical
compositions containing same
    • 法呢基转移酶抑制剂,其制备方法和含有其的药物组合物
    • US5750567A
    • 1998-05-12
    • US875005
    • 1997-07-15
    • Bernard BaudoinChristopher BurnsAlain CommerconAlain Le Brun
    • Bernard BaudoinChristopher BurnsAlain CommerconAlain Le Brun
    • A61K31/195A61K31/215A61P35/00A61P43/00C07C323/25C07C323/59A61K31/21
    • C07C323/25C07C323/59
    • Novel farnesyl transferase inhibitors of general formula (I) ##STR1## preparation thereof and pharmaceutical compositions containing same. In general formula (I), R.sub.1 is Y--S--A.sub.1 -- (where Y is a hydrogen atom, an amino acid residue, a fatty acid residue, or an alkyl or alkoxycarbonyl radical, and A.sub.1 is a C.sub.1-4 alkylene radical optionally .alpha.-substituted in the >C(X.sub.1) (Y.sub.1,) grouping by an amino, alkylamino, alkanoylamino or alkoxycarbonylamino radical wherein the alkyl or alkanoyl portion contains 1-6 carbon atoms; each of X.sub.1 and Y.sub.1 is a hydrogen atom or X.sub.1 and Y.sub.1, taken toether with the carbon atom to which they are attached, form a >C.dbd.O grouping; R'.sub.1 is hydrogen or a C.sub.1-6 alkyl radical; X is an oxygen or sulphur atom; R.sub.2 is a C.sub.1-6 alkyl, alkenyl or alkynyl radical optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulphinyl or alkylsulphonyl.
    • PCT No.PCT / FR96 / 00067 Sec。 371日期1997年7月15日 102(e)日期1997年7月15日PCT 1996年1月16日PCT PCT。 公开号WO96 / 22278 日本1996年7月25日通式(I)的新型法呢基转移酶抑制剂(I)其制备方法和含有其的药物组合物。 在通式(I)中,R 1为YS-A1-(其中Y为氢原子,氨基酸残基,脂肪酸残基或烷基或烷氧羰基,A1为C1-4亚烷基, 在其中烷基或烷酰基部分含有1-6个碳原子的氨基,烷基氨基,烷酰基氨基或烷氧基羰基氨基的基团中被取代> C(X1)(Y1)中的每一个,X1和Y1各自为氢原子或X1和Y1, 与其连接的碳原子一起形成C = O基团; R'1是氢或C1-6烷基; X是氧或硫原子; R2是C1-6烷基,烯基 或任选被羟基,烷氧基,巯基,烷硫基,烷基亚磺酰基或烷基磺酰基取代的炔基。
    • 8. 发明授权
    • Farnesyl transferase inhibitors, their preparation and the
pharmaceutical compositions which contain them
    • 法呢基转移酶抑制剂,它们的制备和含有它们的药物组合物
    • US5861529A
    • 1999-01-19
    • US750819
    • 1997-06-18
    • Bernard BaudoinChristopher BurnsAlain CommerconJean-Dominique Guitton
    • Bernard BaudoinChristopher BurnsAlain CommerconJean-Dominique Guitton
    • C07C323/25C07C323/59C07C323/60A01N37/12
    • C07C323/25C07C323/59C07C323/60C07C2102/08
    • This invention relates to transferase inhibitors of the formula (I), their preparation, and pharmaceutical compositions containing them. ##STR1## In formula (I), R.sub.1 is Y--S--A.sub.1 --(Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl radical, an alkoxycarbonyl radical, or an R.sub.4 --S-- radical in which R.sub.4 is an alkyl radical containing 1 to 4 carbon atoms optionally substituted by a phenyl radical or a radical of the formula (II) ##STR2## in which A.sub.1 is an alkylene radical containing 1 to 4 carbon atoms optionally substituted at the position a in the grouping >C(X.sub.1)(Y.sub.1) with an amino, alkylamino, dialkylamino, alkanoylamino, or alkoxycarbonylamino radical); X.sub.1 and Y.sub.1 are each a hydrogen atom or form, together with the carbon atom to which they are connected, a >C.dbd.O grouping; R'.sub.1 is hydrogen or methyl; R.sub.2 is an alkyl, alkenyl or an alkynyl radical containing 1 to 6 carbon atoms optionally substituted by a hydroxyl, alkoxy, mercapto, alkylthio, alkylsulphinyl, or alkylsulphonyl, wherein when R.sub.2 is an alkyl radical substituted by a hydroxyl radical, R.sub.2 can form a lactone with the carboxyl radical at the .alpha. position; R'.sub.2 is hydrogen or methyl; and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted phenyl radical; and the radical ##STR3## is in position 5 or 6 of the naphthyl ring. These compounds have anti-cancer properties.
    • PCT No.PCT / FR95 / 00739 Sec。 371日期:1997年6月18日 102(e)日期1997年6月18日PCT提交1995年6月7日PCT公布。 第WO95 / 34535号公报 日期1995年12月21日本发明涉及式(I)的转移酶抑制剂,其制备方法和含有它们的药物组合物。 (I)式(I)中,R 1为YS-A1-(Y为氢原子,氨基酸残基,脂肪酸残基,烷基,烷氧基羰基或R4-S-基) 其中R 4是任选被苯基或式(II)的基团取代的含有1至4个碳原子的烷基,其中A 1是含有1至4个碳原子的亚烷基,任选地被取代在 在具有氨基,烷基氨基,二烷基氨基,烷酰基氨基或烷氧基羰基氨基的基团> C(X1)(Y1)中的位置a); X1和Y1各自为氢原子或形式,与它们连接的碳原子一起为> C = O基团; R'1是氢或甲基; R2是任选被羟基,烷氧基,巯基,烷硫基,烷基亚磺酰基或烷基磺酰基取代的含有1至6个碳原子的烷基,烯基或炔基,其中当R2是被羟基取代的烷基时,R2可以形成 内酯与羧基在α位置; R'2是氢或甲基; 并且R是氢原子或任选取代的烷基或任选取代的苯基; 并且基团在萘环的5或6位。 这些化合物具有抗癌特性。